Analysts Maintain Positive Outlook on Protagonist Therapeutics and Bunzl

Investment firms Clear Street and Jefferies reiterated buy ratings for Protagonist Therapeutics, pointing to the commercial strength of its Mimrylo label. Meanwhile, Morningstar affirmed its support for Bunzl, noting that current share prices remain undervalued relative to the company's competitive advantages.